GlassScriptPhysician profile
G A Deandrea
NPI 1437295938
$3,132.66
in general payments reported to CMS, 2019-2025
24 companies · $1,959 in 2025
The $1,959 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2020: $170 · 2021: $90.82 · 2022: $95.37 · 2023: $124 · 2024: $274 · 2025: $1,959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,357.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $573.69 | 2019-2025 | Briviact, Nayzilam |
| Abbvie INC. | $553.89 | 2025 | |
| Biogen, INC. | $260.84 | 2024-2025 | Vumerity, Tysabri |
| Alexion Pharmaceuticals, INC. | $253.28 | 2019-2024 | |
| Novo Nordisk INC | $211.22 | 2025 | Ozempic |
| Boston Scientific Corporation | $194.24 | 2019-2021 | |
| Lundbeck LLC | $175.74 | 2025 | Vyepti |
| Lilly USA, LLC | $133.84 | 2025 | Kisunla, Taltz, Zepbound |
| Medtronic, INC. | $97.89 | 2021-2022 | |
| Avadel Cns Pharmaceuticals, LLC | $93.64 | 2025 | Lumryz |
| Argenx US, INC. | $91.33 | 2024 | Vyvgart |
| Acadia Pharmaceuticals INC | $91.27 | 2020 | |
| Recordati_rare_diseases_inc. | $65.17 | 2025 | Isturisa |
| Medtronic Vascular, INC. | $54.86 | 2020 | |
| Eisai INC. | $40.92 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $40.89 | 2019 | |
| Cycle Pharmaceuticals INC | $32.74 | 2025 | Tascenso Odt, Bafiertam |
| Mallinckrodt Hospital Products INC. | $28.39 | 2025 | Acthar |
| Otsuka America Pharmaceutical, INC. | $26.61 | 2025 | Rexulti |
| W. L. Gore & Associates, INC. | $23.96 | 2020 | |
| Penumbra, INC. | $23.96 | 2022 | |
| Radius Health, INC. | $22.95 | 2025 | Tymlos |
| Kyowa Kirin, INC. | $22.03 | 2025 | |
| Grifols USA, LLC | $19.31 | 2025 | Gamunex-C |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw G Deandrea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.